Novo (NVO) rebrands to regain market share in obesity drugs

Novo Nordisk announced it is rebranding to 'Novo' to improve its market position in the obesity drug sector. Currently, Novo holds a 38.8% market share compared to Eli Lilly's 60.9% as of Q2, according to data cited in a Lilly earnings presentation. The company dropped about 15% in shares this year, despite over 3 million prescriptions for the oral version of Wegovy launched in June. The rebranding includes a cultural shift and new marketing initiatives aimed at building public trust and relevance, which may impact investor perception and stock performance of Novo (NVO).